Drug therapy of overactive bladder - What is coming next?.
10.4111/kju.2015.56.10.673
- Author:
Karl Erik ANDERSSON
- Publication Type:Review
- Keywords:
Cannabinoids;
Purinergic receptors;
Transient receptor potential channels
- MeSH:
Adrenergic beta-3 Receptor Agonists/therapeutic use;
Botulinum Toxins, Type A/therapeutic use;
Drug Therapy, Combination;
Humans;
Molecular Targeted Therapy/methods/trends;
Muscarinic Antagonists/therapeutic use;
Neuromuscular Agents/therapeutic use;
Urinary Bladder, Overactive/*drug therapy
- From:Korean Journal of Urology
2015;56(10):673-679
- CountryRepublic of Korea
- Language:English
-
Abstract:
After the approval and introduction of mirabegron, tadalafil, and botulinum toxin A for treatment of lower urinary tract symptoms/overactive bladder, focus of interest has been on their place in therapy versus the previous gold standard, antimuscarinics. However, since these agents also have limitations there has been increasing interest in what is coming next - what is in the pipeline? Despite progress in our knowledge of different factors involved in both peripheral and central modulation of lower urinary tract dysfunction, there are few innovations in the pipe-line. Most developments concern modifications of existing principles (antimuscarinics, beta3-receptor agonists, botulinum toxin A). However, there are several new and old targets/drugs of potential interest for further development, such as the purinergic and cannabinoid systems and the different members of the transient receptor potential channel family. However, even if there seems to be good rationale for further development of these principles, further exploration of their involvement in lower urinary tract function/dysfunction is necessary.
